NASDAQ: LVTXLava Therapeutics Nv Stock
$1.30+0.02 (+1.56%)
Updated Mar 27, 2025
LVTX Price
$1.30
Fair Value Price
N/A
Market Cap
$34.19M
52 Week Low
$0.85
52 Week High
$3.57
P/E
-1.22x
P/B
0.98x
P/S
5.46x
PEG
N/A
Dividend Yield
N/A
Revenue
$7.73M
Earnings
-$30.71M
Gross Margin
97.9%
Operating Margin
-383.64%
Profit Margin
-376.4%
Debt to Equity
1.53
Operating Cash Flow
-$31M
Beta
0.39
Next Earnings
May 19, 2025
Ex-Dividend
N/A
Next Dividend
N/A
LVTX Overview
LAVA Therapeutics N.V. offers Gammabody platform, a portfolio of novel bispecific antibodies that engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. The company's lead clinical-stage candidates are LAVA-051, in Phase 1/2a clinical trials for blood cancers (chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia), and LAVA-1207, in Phase 1/2a clinical trials for metastatic castration-resistant prostate cancer. LAVA Therapeutics was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine LVTX's potential to beat the market
- LVTX doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
LVTX
RankedUnranked of 477
RankedUnranked of 477
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.58 | A | |
| $8.46 | A | |
| $126.40 | A |
Be the first to know about important LVTX news, forecast changes, insider trades & much more!
LVTX News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how LVTX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
LVTX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
LVTX is good value based on its book value relative to its share price (0.98x), compared to the US Biotechnology industry average (4.52x)
P/B vs Industry Valuation
LVTX is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more LVTX due diligence checks available for Premium users.
Valuation
LVTX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.22x
Industry
-123.64x
Market
31.08x
LVTX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.98x
Industry
4.52x
LVTX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
LVTX's financial health
Profit margin
Revenue
$0.0
Net Income
-$13.7M
Profit Margin
0%
LVTX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
LVTX's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$92.6M
Liabilities
$56.0M
Debt to equity
1.53
LVTX's short-term assets ($85.83M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
LVTX's short-term assets ($85.83M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
LVTX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$9.6M
Investing
$496.7k
Financing
-$408.9k
LVTX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
LVTX vs Biotech Stocks
Lava Therapeutics Nv Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.